187 related articles for article (PubMed ID: 24165884)
1. The effect of single- and multiple-dose etravirine on a drug cocktail of representative cytochrome P450 probes and digoxin in healthy subjects.
Kakuda TN; Van Solingen-Ristea RM; Onkelinx J; Stevens T; Aharchi F; De Smedt G; Peeters M; Leopold L; Hoetelmans RM
J Clin Pharmacol; 2014 Apr; 54(4):422-31. PubMed ID: 24165884
[TBL] [Abstract][Full Text] [Related]
2. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
[TBL] [Abstract][Full Text] [Related]
3. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
[TBL] [Abstract][Full Text] [Related]
5. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
[TBL] [Abstract][Full Text] [Related]
6. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Ermer J; Corcoran M; Martin P
Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
8. Assessment of Pharmacokinetic Interactions Between Obeticholic Acid and Caffeine, Midazolam, Warfarin, Dextromethorphan, Omeprazole, Rosuvastatin, and Digoxin in Phase 1 Studies in Healthy Subjects.
Edwards JE; Eliot L; Parkinson A; Karan S; MacConell L
Adv Ther; 2017 Sep; 34(9):2120-2138. PubMed ID: 28808886
[TBL] [Abstract][Full Text] [Related]
9. Lopinavir/ritonavir induces the hepatic activity of cytochrome P450 enzymes CYP2C9, CYP2C19, and CYP1A2 but inhibits the hepatic and intestinal activity of CYP3A as measured by a phenotyping drug cocktail in healthy volunteers.
Yeh RF; Gaver VE; Patterson KB; Rezk NL; Baxter-Meheux F; Blake MJ; Eron JJ; Klein CE; Rublein JC; Kashuba AD
J Acquir Immune Defic Syndr; 2006 May; 42(1):52-60. PubMed ID: 16639344
[TBL] [Abstract][Full Text] [Related]
10. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
Kim MG; Kim Y; Jeon JY; Kim DS
Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
[TBL] [Abstract][Full Text] [Related]
11. Effect of a triphasic oral contraceptive on drug-metabolizing enzyme activity as measured by the validated Cooperstown 5+1 cocktail.
Shelepova T; Nafziger AN; Victory J; Kashuba AD; Rowland E; Zhang Y; Sellers E; Kearns G; Leeder JS; Gaedigk A; Bertino JS
J Clin Pharmacol; 2005 Dec; 45(12):1413-21. PubMed ID: 16291717
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.
Kakuda TN; Van Solingen-Ristea R; Aharchi F; Smedt GD; Witek J; Nijs S; Vyncke V; Hoetelmans RM
J Clin Pharmacol; 2013 Jan; 53(1):41-50. PubMed ID: 23400742
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodeficiency virus entry inhibitor, using a modified cooperstown 5 + 1 cocktail.
Johnson BM; Song IH; Adkison KK; Borland J; Fang L; Lou Y; Berrey MM; Nafziger AN; Piscitelli SC; Bertino JS
J Clin Pharmacol; 2006 May; 46(5):577-87. PubMed ID: 16638741
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
15. Effect of tildrakizumab (MK-3222), a high affinity, selective anti-IL23p19 monoclonal antibody, on cytochrome P450 metabolism in subjects with moderate to severe psoriasis.
Khalilieh S; Hussain A; Montgomery D; Levine V; Shaw PM; Bodrug I; Mekokishvili L; Bailey-Smith C; Glasgow XS; Cheng A; Martinho M; Iwamoto M
Br J Clin Pharmacol; 2018 Oct; 84(10):2292-2302. PubMed ID: 29926968
[TBL] [Abstract][Full Text] [Related]
16. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
17. Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects.
Greene SA; Kwak C; Kamin M; Vernillet L; Glenn KJ; Gabriel L; Kim HW
Clin Transl Sci; 2022 Apr; 15(4):899-911. PubMed ID: 34877801
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study in patients with rheumatoid arthritis using a cocktail approach.
Zhuang Y; de Vries DE; Xu Z; Marciniak SJ; Chen D; Leon F; Davis HM; Zhou H
J Clin Pharmacol; 2015 Dec; 55(12):1386-94. PubMed ID: 26054042
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic evaluation of the interaction between etravirine and rifabutin or clarithromycin in HIV-negative, healthy volunteers: results from two Phase 1 studies.
Kakuda TN; Woodfall B; De Marez T; Peeters M; Vandermeulen K; Aharchi F; Hoetelmans RM
J Antimicrob Chemother; 2014 Mar; 69(3):728-34. PubMed ID: 24155058
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic interaction between etravirine or darunavir/ritonavir and artemether/lumefantrine in healthy volunteers: a two-panel, two-way, two-period, randomized trial.
Kakuda TN; DeMasi R; van Delft Y; Mohammed P
HIV Med; 2013 Aug; 14(7):421-9. PubMed ID: 23441978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
